DEKA Laser and New York’s Romeo & Juliette: A Global Partnership for Advanced Epilation on Fifth Avenue
4.12.2024 13:00:00 CET | Business Wire | Press release
DEKA Laser, global leader in medical laser technologies, proudly announces its new and prestigious partnership with Romeo & Juliette Hair Removal, the renowned center specialized in permanent hair removal located on world-famous Fifth Avenue in New York City. Thanks to this exclusive collaboration, Romeo & Juliette will become another global reference center for DEKA training on laser hair removal, with particular attention to the Again PRO Series line of equipment, and will host the innovative DEKA Epil Academy, an academy dedicated to the training and sharing of advanced hair removal treatment protocols.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204652458/en/
Located on one of the most elegant and most renowned avenues in the world, Romeo & Juliette Hair Removal is considered true excellence in the aesthetic and medical realm, and is frequented by celebrities, top models and prominent sports personalities. This new international training center will become the reference point for physicians and specialists from all over the world who wish to train on the most innovative and effective laser hair removal protocols, in particular for the treatment of all phototypes.
“The collaboration with Romeo & Juliette represents a significant achievement for DEKA”, says Paolo Salvadeo, DEKA Laser’s CEO. “This partnership allows us to take our quality and innovation standards to one of the most iconic and prestigious locations in the world, making the training experience unique in its type. I am proud to be able to give life to this project, which will contribute to the growth and diffusion of the Again PRO technology and our advanced hair removal protocols.
Also Chris Karavolas, Director of the Romeo & Juliette Center, expresses his enthusiasm for this new phase: “We are thrilled to cooperate with DEKA, a subsidiary of the El.En. Group, an absolute reference company in the world of laser technology. This synergy will allow us to offer cutting-edge treatments to our clients, constantly optimizing the protocols for every skin type. For us working side by side with DEKA and El.En. Group represents a unique growth and development opportunity”.
Chris Karavolas, with over twenty years of experience in the hair removal field, will work closely with the DEKA team to perfect the treatment protocols for every skin type, contributing to positioning Romeo & Juliette and DEKA Laser as global leaders in the sector.
The DEKA Epil Academy will position itself as a center of excellence in the hair removal training, attracting professionals the world over toward the famous Fifth Avenue, a meeting place of innovation, beauty and technology.
https://dekalaser.com/products/again-pro/
https://www.romeojuliettelaserhairremoval.com/
Information on DEKA
DEKA is a subsidiary of the EL.EN. multinational Group which has been the leader in the laser work for 40 years.
This Italian company, headquartered in Florence, has its roots in a culture whose dominant characteristic is excellence of thought. Thanks to its priceless cultural heritage and its unique historical background, DEKA enshrines a promise of universal value in its vision: Transforming each scientific discovery into a solid benefit for physicians and patients and translate each technological innovation into ongoing improvement in its product and services range to ameliorate the quality of people’s lives.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204652458/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom